Opioid-induced constipation

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 11, 2015, Pages 1331-1338

  Gyawali, Bishal ^a   Hayashi, Naomi ^a   Tsukuura, Hiroaki ^a   Honda, Kazunori ^a   Shimokata, Tomoya ^a   Ando, Yuichi ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Doctor patient communication; Laxatives; Linaclotide; Lubiprostone; Opioid induced constipation; Opioid naloxone combination; Opioids; Peripherally acting mu opioid receptor antagonists; Tapentadol

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; MU OPIATE RECEPTOR ANTAGONIST; NALOXEGOL; NALOXONE; OPIATE; OPIATE ANTAGONIST; OXYCODONE; TAPENTADOL; CHLORIDE CHANNEL STIMULATING AGENT; MU OPIATE RECEPTOR; PEPTIDE; PHENOL DERIVATIVE;

ANALGESIA; ARTICLE; BLOOD BRAIN BARRIER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL (TOPIC); CONSTIPATION; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FIBER; HUMAN; OPIOID INDUCED CONSTIPATION; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHYDRATION; AGONISTS; CHEMICALLY INDUCED; CHRONIC PAIN;

CHLORIDE CHANNEL AGONISTS; CHRONIC PAIN; CONSTIPATION; HUMANS; LAXATIVES; LUBIPROSTONE; NALOXONE; OXYCODONE; PEPTIDES; PHENOLS; RECEPTORS, OPIOID, MU;

EID: 84945189702     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2015.1054423     Document Type: Article

References (54)

1. WHO's cancer pain ladder for adults. WHO. Available at http://www.who.int/cancer/palliative/painladder/en/.
2. Kenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010. Open Med 2012;6:e41-7.
3. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63:649-71.
4. Holmes S. Use of a modified symptom distress scale in assessment of the cancer patient. Int J Nurs Stud 1989;26: 69-79.
5. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004;16:17-28.
6. Stefano GB, Goumon Y, Casares F, Cadet P, Fricchione GL, Rialas C, et al. Endogenous morphine. Trends Neurosci 2000;23:436-42.
7. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-80.
8. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182:11S-8S.
9. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009;10: 35-42.
10. Rogers M, Cerda JJ. The narcotic bowel syndrome. J Clin Gastroenterol 1989;11:132-5.
11. Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007; 5:1126-39; quiz 1121-1122.
12. Droney J, Ross J, Gretton S, Welsh K, Sato H, Riley J. Constipation in cancer patients on morphine. Support Care Cancer 2008;16:453-9.
13. Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, et al. Methylnaltrexone for opioidinduced constipation in advanced illness. N Engl J Med 2008;358:2332-43.
14. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011;106: 835-42; quiz 843.
15. Tamayo AC, Diaz-Zuluaga PA. Management of opioidinduced bowel dysfunction in cancer patients. Support Care Cancer 2004;12:613-18.
16. Ahmedzai SH, Boland J. Constipation in people prescribed opioids. BMJ Clin Evid 2010;4:2407.
17. Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, et al. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain 2012;28:373-81.
18. Villars P, Dodd M, West C, Koetters T, Paul SM, Schumacher K, et al. Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. J Pain Symptom Manage 2007;33:67-77.
19. Rosti G, Gatti A, Costantini A, Sabato AF, Zucco F. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci 2010;14: 1045-50.
20. De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004;16:383-94.
21. Manara L, Bianchetti A. The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol 1985;25:249-73.
22. Reimer K, Hopp M, Zenz M, Maier C, Holzer P, Mikus G, et al. Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach. Pharmacology 2009;83:10-17.
23. Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011:CD003448.
24. Tack J. Current and future therapies for chronic constipation. Best Pract Res Clinl Gastroenterol 2011;25:151-8.
25. Latasch L, Zimmermann M, Eberhardt B, Jurna I. Treament of morphine-induced constipation with oral naloxone. Anaesthesist 1997;46:191-4.
26. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, Foley K, Houde RW, Marsh F, et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1992;52:90-5.
27. Holzer P. New approaches to the treatment of opioidinduced constipation. Eur Rev Med Pharmacol Sci 2008; 12:119-27.
28. Bream-Rouwenhorst HR, Cantrell MA. Alvimopan for postoperative ileus. Am J Health Syst Pharm 2009;66: 1267-77.
29. Jansen JP, Lorch D, Langan J, Lasko B, Hermanns K, Kleoudis CS, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with noncancer pain. J Pain 2011;12:185-93.
30. Bader S, Jaroslawski K, Blum HE, Becker G. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insight Oncol 2011;5:201-11.
31. Yuan CS, Foss JF, O'Connor M, Karrison T, Osinski J, Roizen MF, et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther 2000;67:398-404.
32. Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996;59:469-75.
33. Diego L, Atayee R, Helmons P, von Gunten CF. Methylnaltrexone: a novel approach for the management of opioidinduced constipation in patients with advanced illness. Expert Rev Gastroenterol Hepatol 2009;3:473-85.
34. Cryer B, Katz S, Vallejo R, Popescu A, Ueno R. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 2014;15:1825-34.
35. Mackey AC, Green L, Greene P, Avigan M. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage 2010;40:e1-3.
36. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014; 370:2387-96.
37. Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 2010;14:781-3.
38. Bee LA, Bannister K, Rahman W, Dickenson AH. Mu-opioid and noradrenergic alpha(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain 2011;152:131-9.
39. Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, et al. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Invest 2010;30:489-505.
40. Buynak R, Shapiro DY, Okamoto A, Van Hove I, Rauschkolb C, Steup A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother 2010;11:1787-804.
41. Candiotti KA, Gitlin MC. Review of the effect of opioidrelated side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Curr Med Res Opin 2010;26:1677-84.
42. Imanaka K, Tominaga Y, Etropolski M, van Hove I, Ohsaka M, Wanibe M, et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin 2013;29: 1399-409.
43. Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician 2014;17:329-43.
44. Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain 2000;84:105-9.
45. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996;10:135-44.
46. Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54.
47. Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64.
48. DePriest AZ, Miller K. Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence. Pain Ther 2014;3:1-15.
49. Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527-36.
50. Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin Gastroenterol 2007;41:345-51.
51. NCCN Guidelines Adult Cancer Pain (Version 2.2013). Available at http://www.nccn.org/professionals/physician-gls/PDF/pain.pdf.
52. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996;64:527-34.
53. Mystakidou K, Tsilika E, Parpa E, Kouloulias V, Kouvaris I, Georgaki S, et al. Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Cancer J 2003;107:486-92.
54. Gyawali B, Tsukuura H, Honda K, Shimokata T, Ando Y. Some questions on the randomized controlled trial of communication skills training for oncologists. J Clin Oncol 2015;33:222.